BiopharmaNKTR

Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company developing immunomodulatory therapeutics, including the regulatory-T-cell-stimulating IL-2 conjugate rezpegaldesleukin for inflammatory and autoimmune diseases.

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Diseases

Nektar Therapeutics forecasting benchmarks

1 benchmark

ResolvedPhase 2b

REZOLVE-AA (rezpegaldesleukin) Phase 2b alopecia areata

Rezpegaldesleukin · Alopecia areata

Dec 16, 2025Clinical Trials

Pipeline on the platform

Rezpegaldesleukin· Treg-selective IL-2 conjugate

Therapeutic areas

Alopecia areata· AA

About Nektar Therapeutics

What is Nektar Therapeutics developing?

Which Nektar Therapeutics trials can I forecast?

We track 1 Nektar Therapeutics trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

References

Keep exploring

All benchmarks Diseases Drugs Targets & genes